Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab plus tislelizumab versus durvalumab after concurrent chemoradiotherapy in PD-L1-positive unresectable stage III non-small cell lung cancer
NL-OMON52181Phase 3Withdrawn
- Sponsor
- BeiGene
- Start
- Jul 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ociperlimab, tislelizumab and durvalumab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: withdrawn.
02
Drugs
ociperlimabtislelizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52181.